665. Deputy Ken O'Flynn asked the Minister for Health to identify the official, office, unit or governance structure with final responsibility for oversight of the treatment abroad scheme; and to set out the reporting line between that function, the HSE and their Department. [41234/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Departmental Data.
651 questions match, newest first.
666. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme is subject to a formal written governance framework, programme charter, oversight protocol or internal control framework; if so, when it was approved and last reviewed. [41235/26]
668. Deputy Ken O'Flynn asked the Minister for Health whether any annual governance review, assurance statement, compliance certification or similar review is completed in respect of the treatment abroad scheme. [41237/26]
669. Deputy Ken O'Flynn asked the Minister for Health whether any designated officer is responsible for ensuring value-for-money compliance, expenditure control and public financial governance in respect of the treatment abroad scheme. [41238/26]
670. Deputy Ken O'Flynn asked the Minister for Health whether any cumulative annual expenditure threshold under the treatment abroad scheme triggers enhanced review, senior management escalation or Departmental notification. [41239/26]
671. Deputy Ken O'Flynn asked the Minister for Health whether any per-patient expenditure threshold applies under the treatment abroad scheme and whether high-cost cases require separate financial approval distinct from clinical approval. [41240/26]
672. Deputy Ken O'Flynn asked the Minister for Health whether retrospective expenditure analysis is carried out to identify outlier costs, repeated high-cost providers, abnormal billing patterns or unusual procedure-level expenditure under the treatment abroad scheme. [41241/26]
673. Deputy Ken O'Flynn asked the Minister for Health whether any formal mechanism exists to benchmark the cost of procedures funded under the treatment abroad scheme against comparable costs in other EU or EEA jurisdictions. [41242/26]
674. Deputy Ken O'Flynn asked the Minister for Health whether any procurement, commissioning, preferred-provider or provider-assurance framework exists where overseas providers are used repeatedly under the treatment abroad scheme. [41243/26]
676. Deputy Ken O'Flynn asked the Minister for Health whether patient-reported outcome measures are collected in respect of procedures funded under the treatment abroad scheme. [41245/26]
677. Deputy Ken O'Flynn asked the Minister for Health whether any mechanism exists to suspend, restrict, review or escalate referrals to an overseas provider where concerns arise regarding outcomes, standards, billing or patient safety. [41246/26]
679. Deputy Ken O'Flynn asked the Minister for Health whether their Department has reviewed the adequacy of current governance, audit, expenditure-control and outcome-monitoring arrangements for the treatment abroad scheme since 2020; and if so, to provide the date and outcome of that review. [41248/26]
680. Deputy Ken O'Flynn asked the Minister for Health whether their Department distinguishes, for governance purposes, between treatments unavailable in the State due to capacity constraints and treatments unavailable due to policy, clinical, ethical or regulatory considerations. [41249/26]
681. Deputy Ken O'Flynn asked the Minister for Health whether any additional governance safeguards apply where the State funds, through the treatment abroad scheme, procedures which are not routinely provided within the Irish public healthcare system. [41250/26]
682. Deputy Ken O'Flynn asked the Minister for Health whether any external body, including HIQA, the HSE Internal Audit function, the Comptroller and Auditor General or another assurance body, has been asked since 2020 to review the governance, expenditure control or patient-safety oversight of the treatment abroad scheme. [41251/26]
683. Deputy Ken O'Flynn asked the Minister for Health whether the Department has received any advice, briefing or internal submission since 2020 on the financial, clinical or governance risks associated with the treatment abroad scheme. [41252/26]
684. Deputy Ken O'Flynn asked the Minister for Health whether they will commission an independent governance and value-for-money review of the treatment abroad scheme, having regard to public expenditure, patient safety, outcome monitoring and cross-border provider oversight. [41253/26]
728. Deputy Ken O'Flynn asked the Minister for Health the total number of medical malpractice claims or clinical negligence cases lodged against the HSE or HSE-funded hospitals in 2024, 2025, and to date in 2026; the number of such cases that have been settled or concluded; the total cost of settlements and awards in each of those years; and if she will make a statement on the matter. [41309/26]
19. Deputy Ken O'Flynn asked the Minister for Defence whether any equipment, software, avionics, communications systems, sensor systems, mission systems, cybersecurity systems, electronic warfare components, or other defence-related technologies currently in operational use within the Defence Forces were manufactured, developed, licensed, or supplied by companies headquartered in Israel or by subsidiaries of Israeli …
20. Deputy Ken O'Flynn asked the Minister for Defence whether any assessment has been undertaken by her Department or the Defence Forces regarding the procurement, operational use, maintenance, licensing, or integration of Israeli-origin defence technologies or software within Defence Forces platforms or systems; and if she will make a statement on the matter. [40581/26]
21. Deputy Ken O'Flynn asked the Minister for Defence whether any Israeli-manufactured, Israeli-developed, or Israeli-origin components, software, mission systems, avionics, communications equipment, cybersecurity tools, sensors, or licensed technologies form part of the Airbus H145M helicopter fleet acquired for the Air Corps; and whether ministerial approval, departmental review, export-control clearance, or legal …
22. Deputy Ken O'Flynn asked the Minister for Defence whether her Department maintains any policy, guidance framework, procurement restriction, ethical screening mechanism, or due diligence process relating to the acquisition or use of defence-related systems, software, or technologies originating from jurisdictions subject to significant international controversy or armed conflict; and if she will provide details. […
23. Deputy Ken O'Flynn asked the Minister for Defence whether the Defence Forces or her Department maintain a register, inventory classification, or procurement record identifying the country of origin of major defence-related software, avionics, communications systems, sensors, or mission-critical technologies currently in use across Defence Forces platforms. [40584/26]
24. Deputy Ken O'Flynn asked the Minister for Defence whether any third-party systems integrators, subcontractors, or original equipment manufacturers involved in Defence Forces procurement programmes utilise Israeli-developed software, firmware, avionics architecture, cybersecurity tools, sensor technology, or communications systems as part of integrated defence platforms supplied to the State. [40585/26]
25. Deputy Ken O'Flynn asked the Minister for Defence whether the Department or Defence Forces require prime defence contractors to disclose the origin country of embedded software, avionics systems, communications architecture, sensors, mission systems, or cybersecurity components supplied under State defence procurement contracts. [40586/26]